Health & Biotech
Prescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers.
Prescient’s CAR-T and targeted therapies are personalised medicine approaches that aim to improve patient outcomes.
Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Prescient has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.
Prescient Therapeutics is working to rapidly expand the application of universal CAR-T therapies, capable of addressing all cancers, including solid tumours.
OmniCAR, a universal CAR-T platform employing technology licensed from UPenn, the pioneer and world leader in CAR-T, as well as Oxford University, will allow unprecedented control and flexibility over current generation CAR-T approaches. It combines the cancer-killing capabilities of a T-cell with the control and pharmacology of a drug.
CellPryme-M is a high-performance platform for enhancing cell therapy manufacturing that results in cell products with superior phenotypes that are longer lasting and more efficacious. It involves a single, rapid step that can be easily accommodated within standard cell manufacturing protocols. CellPryme-M was developed by Prescient in collaboration with the Peter MacCallum Cancer Centre, with Prescient retaining whole ownership of intellectual property.
Further to this, Prescient is working with leading CAR-T innovators to develop other improved CAR-T approaches.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Prescient launches capital raise to progress pipeline of cancer therapies
Health & Biotech
Prescient secures OmniCAR cell lines for upcoming clinical trials
Health & Biotech
ASX Health Stocks: Emyria on a high after getting ethics approval, Twiggy’s investment
News
ASX Quarterlies: From fintech to biotech, these small caps have delivered strong performances for shareholders
Health & Biotech
Prescient first in class cancer drug PTX-100 granted Orphan Drug status by the US FDA
News
ASX Small Cap Lunch Wrap: Who’s finding new ways to win a horse race today?
News
Top 10 at 10: Which ASX stocks are cruising and snoozing today?
Health & Biotech
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
Health & Biotech
ASX Health Stocks: US patent another Prescient win for booming Aussie biotechs
Health & Biotech
Check Up: Biotechs are getting crushed, but expert says we shouldn’t dismiss them
Health & Biotech
Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Health & Biotech
Check Up: Is biotech a good investment in a higher rate cycle? Turns out theory is just a theory
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Between rocks and a hard place (to get COVID), small caps crash and stimmy hopes dash on China lockdowns
News
Meet the pain: Eddy quaffed all these small cap quarterlies and we saved you the best bits
Health & Biotech
Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death
Health & Biotech